

Covid-19 vaccine pipeline builds as Clover and Dynavax push on



Amy Brown

Several late-stage Covid-19 vaccine successes have not deterred developers working on earlier projects, and today [Clover became the latest to announce](#) a move into phase II/III, with a vaccine codenamed SCB-2019. The move is notable because the China biotech is proceeding with a Dynavax adjuvant, rather than one made by Glaxosmithkline. A [study of both vaccine-adjuvant combinations](#) found that immune responses were lower when SCB-2019 was adjuvanted with Dynavax's CpG/Alum, as opposed to Glaxo's AS03, though the authors stressed that the data could not be extrapolated to infer protection. Clover apparently saw enough to push on with CpG/Alum, although it might not have had a choice; Glaxo could well have chosen to prioritise the two other vaccine projects that utilise AS03. The adjuvant is also being used in a Medicago project, and in the delayed Sanofi vaccine collaboration. A spokesperson for the UK pharma giant told *Evaluate Vantage* that manufacturing capacity had no bearing on the move. With [big names in vaccine development failing](#) to progress it is encouraging to see a full pipeline coming behind the leaders, although maybe the bar to push on is lower for those with smaller commercial vision.

Coming behind: the second wave of Covid-19 vaccines?

Project	Description	Company	Update
CVnCoV	mRNA (2 dose)	Curevac	Herald , Europe ph2/3 data due Q1 2021; Europe ph3 due 2021
Ad5-nCoV	Adenovirus type 5 vaccine (1 dose)	Cansino Biologics	Ph3 recruiting in Russia & S America
Coronavirus-like particle Covid-19 vaccine	Coronavirus-like particle vaccine (2 dose)	GSK/Medicago	Ph2/3 started Nov 2020 in Canada & US
Covid-19 S-Trimer	Trimerised fusion protein (2 dose)	Clover/Dynavax	Ph2/3 to start H1 2021; interim analysis due mid-2021
Covid-19 vaccine project	Recombinant protein (1 or 2 dose tbc)	Sanofi/Glaxo	Ph3 due to start 2021, pending development of new formulation
INO-4800	DNA vaccine (2 dose)	Inovio	Ph2 stage of pivotal study recruiting; ph3 stage remains on US hold; ph2 enrolling in China
ARCT-021	Self-amplifying mRNA vaccine (1 or 2 dose tbc)	Arcturus	Ph3 planned for Q2 2021 pending data from ongoing Ph2
ZyCoV-D	DNA vaccine (3 doses)	Zyodus Cadila	Ph3 cleared to start in India Jan 2021

Note: includes notable projects already progressed into phase II/III development or likely to do so imminently. List not exhaustive. Source: EvaluatePharma & company statements.

[More from Evaluate Vantage](#)

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
[+1-617-573-9450](tel:+16175739450)

Evaluate APAC
[+81-\(0\)80-1164-4754](tel:+8108011644754)

© Copyright 2022 Evaluate Ltd.